Abstract
Alterations of the ubiquitin proteasome system (UPS) contribute to the progression of many diseases, such as cancer, neurodegenerative diseases, immunological disorders, and inflammation. Pharmacologic inhibition of specific ubiquitin regulatory enzymes and ubiquitination events is an important challenge in drug discovery. Identifying the substrates of the various enzymes that participate in the UPS is needed to determine which enzymes are potential drug candidates. Additionally, identifying the ubiquitination events regulated by pharmacological drugs can potentially discover new applications. In this review we describe mass spectrometry-based proteomic approaches for the identification of ubiquitinated proteins and their modification sites on a proteome-wide scale, focusing on the ubiquitin remnant profiling, a newly developed ubiquitination profiling technique. We then discuss the application of this approach for the profiling of ubiquitination events regulated by cell signaling pathways and explore its future applications for drug discovery in the UPS.
Keywords: Ubiquitin proteasome system, ubiquitin remnant-containing peptide, ubiquitin remnant profiling, drug discovery, LC-MS/MS.
Current Pharmaceutical Design
Title:Comprehensive Profiling of Protein Ubiquitination for Drug Discovery
Volume: 19 Issue: 18
Author(s): Guoqiang Xu and Samie R. Jaffrey
Affiliation:
Keywords: Ubiquitin proteasome system, ubiquitin remnant-containing peptide, ubiquitin remnant profiling, drug discovery, LC-MS/MS.
Abstract: Alterations of the ubiquitin proteasome system (UPS) contribute to the progression of many diseases, such as cancer, neurodegenerative diseases, immunological disorders, and inflammation. Pharmacologic inhibition of specific ubiquitin regulatory enzymes and ubiquitination events is an important challenge in drug discovery. Identifying the substrates of the various enzymes that participate in the UPS is needed to determine which enzymes are potential drug candidates. Additionally, identifying the ubiquitination events regulated by pharmacological drugs can potentially discover new applications. In this review we describe mass spectrometry-based proteomic approaches for the identification of ubiquitinated proteins and their modification sites on a proteome-wide scale, focusing on the ubiquitin remnant profiling, a newly developed ubiquitination profiling technique. We then discuss the application of this approach for the profiling of ubiquitination events regulated by cell signaling pathways and explore its future applications for drug discovery in the UPS.
Export Options
About this article
Cite this article as:
Xu Guoqiang and Jaffrey Samie R., Comprehensive Profiling of Protein Ubiquitination for Drug Discovery, Current Pharmaceutical Design 2013; 19 (18) . https://dx.doi.org/10.2174/13816128113199990305
DOI https://dx.doi.org/10.2174/13816128113199990305 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member:
Current Medicinal Chemistry Chemotherapeutic Properties of n-3 Polyunsaturated Fatty Acids - Old Concepts and New Insights
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Experimental Therapy for Lung Cancer: Umbilical Cord-Derived Mesenchymal Stem Cell-Mediated Interleukin-24 Delivery
Current Cancer Drug Targets Application of Serial Analysis of Gene Expression in Cancer Research
Current Pharmaceutical Biotechnology Nanoparticles-Based Treatment for Bone Metastasis
Current Drug Targets The Novel RARβ Isoform (β 5) is a Potential Target of Retinoids in Breast Cancer
Current Cancer Drug Targets Clinical, Prognostic and Therapeutic Significance of Heat Shock Proteins in Cancer
Current Drug Targets Fusion of MLO and CC View Binary Patterns to Improve the Performance of Breast Cancer Diagnosis
Current Medical Imaging Circulating Levels of Soluble Angiogenic Factors in Multiple Myeloma: Correlation with Parameters of Disease Activity and Prognosis
Current Angiogenesis (Discontinued) The mTOR Pathway: A New Target in Cancer Therapy
Current Cancer Drug Targets Tamoxifen and Fulvestrant Hybrids Showed Potency as Selective Estrogen Receptor Down-Regulators
Medicinal Chemistry CYP19A1 rs10046 Pharmacogenetics in Postmenopausal Breast Cancer Patients Treated with Aromatase Inhibitors: One-year Follow-up
Current Pharmaceutical Design Preclinical Analyses of the Therapeutic Potential of Allopregnanolone to Promote Neurogenesis In Vitro and In Vivo in Transgenic Mouse Model of Alzheimers Disease
Current Alzheimer Research Challenges and Opportunities in Molecular Imaging
Current Medical Imaging Drug Interactions with Normal and TEN Epidermal Keratinocytes
Current Drug Safety siRNA Delivery Using Nanocarriers – An Efficient Tool for Gene Silencing
Current Gene Therapy Modulation of Signaling Enhances the Efficacy of the Combination of Satraplatin and Erlotinib
Current Drug Targets A Tropical Lichen, Dirinaria consimilis Selectively Induces Apoptosis in MCF-7 Cells through the Regulation of p53 and Caspase-Cascade Pathway
Anti-Cancer Agents in Medicinal Chemistry Clinical Management of Infectious Diarrhea
Reviews on Recent Clinical Trials